pegfilgrastim
Aliases
filgrastim-SD/01, Filgrastim SD-01, Fulphila, HSP-130, Jinyouli (11 other aliases)
16 clinical trials
9 abstracts
20 indications
Indication
Breast CancerIndication
Breast Cancer, Stage IIIndication
BreastIndication
lymphomaIndication
NeutropeniaIndication
Follicular LymphomaIndication
Recurrent Diffuse Large B-Cell LymphomaIndication
Recurrent Follicular LymphomaIndication
Diffuse Large B-Cell LymphomaIndication
Non-Hodgkin lymphomaIndication
Testicular NeoplasmsIndication
LeukemiaIndication
Brain and Central Nervous System TumorsIndication
Drug/Agent Toxicity by Tissue/OrganIndication
ThrombocytopeniaIndication
Multiple MyelomaIndication
AIDS-related lymphomaIndication
Diffuse Large B-cell LymphomaIndication
Adult Diffuse Large Cell LymphomaClinical trial
Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express Human Epidermal Growth Factor Receptor 2 (HER-2)/NeuStatus: Terminated, Estimated PCD: 2010-11-18
Abstract
Comparative analysis of efficacy and safety profiles between conventional pegfilgrastim and its biosimilar agents in patients receiving cytotoxic chemotherapy: A systemic review and meta-analysis.Org: Pakistan,
Abstract
A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide.Org: National University Cancer Institute, National University Health Systems, National Cancer Institute, Vilnius, Lithuania,
Clinical trial
Self-Reported Pain and Nadir White Blood Cell/Absolute Neutrophil Count in Women 45 and Under Compared to Older Women Receiving Pegfilgrastim (or Biosimilar Substitution) While Undergoing Chemotherapy for Non-Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2041-01-01
Abstract
Safety in the use of granulocyte-colony stimulating factor during concurrent chemotherapy and thoracic radiotherapy in patients with small-cell lung cancer: A meta-analysis.Org: UNICAMP - State University of Campinas, Santa Marcelina College, Afya, Unipam, Evangélica University of Goiás,
Clinical trial
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's LymphomaStatus: Completed, Estimated PCD: 2001-02-01
Clinical trial
BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's LymphomaStatus: , Estimated PCD: 2010-01-01
Clinical trial
Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2015-01-01
Clinical trial
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2021-05-07
Clinical trial
A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast CancerStatus: Completed, Estimated PCD: 2010-01-06
Clinical trial
A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular LymphomaStatus: Terminated, Estimated PCD: 2022-04-27
Clinical trial
GAMEC-SHORT (S) & GAMEC-ANTHRACYCLINE(A) (Combination Chemotherapy With GCSF, Actinomycin-D, Methotrexate, Etoposide and Cisplatin) Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)Status: Completed, Estimated PCD: 2013-06-01
Clinical trial
A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin LymphomaStatus: Completed, Estimated PCD: 2016-01-31
Clinical trial
A Phase III Randomized Study of EC Followed by Paclitaxel Versus FEC Followed by Paclitaxel, All Given Either Every 3 Weeks or 2 Weeks Supported by Pegfilgrastim, for Node Positive Breast Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2006-05-01
Clinical trial
An Open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide and Rituximab in Patients With Chronic Lymphocytic Leukaemia Who Are Newly Diagnosed, Have Relapsed or Are Resistant to First-Line TreatmentStatus: Completed, Estimated PCD: 2019-11-21
Clinical trial
A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment RegimenStatus: Terminated, Estimated PCD: 2010-06-01
Clinical trial
Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilgrastim for Neutrophil Recovery After Autologous Stem Cell TransplantStatus: Completed, Estimated PCD: 2023-02-25
Clinical trial
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related LymphomasStatus: Recruiting, Estimated PCD: 2025-06-20
Clinical trial
A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell LymphomaStatus: Completed, Estimated PCD: 2021-07-20
Abstract
Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up.Org: American Oncology Network Pharmacy, Fort Myers, FL,
Abstract
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.Org: Adult Bone Marrow Transplant Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Myeloma Service, BeyondSpring Pharmaceuticals, Inc.,
Abstract
Safety of same day administration of pegfilgrastim in breast cancer patients.Org: University of Alabama-Birmingham, Washington St Louis University, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Wake Forest Baptist Comprehensive Cancer Center,
Abstract
Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer.Org: Hospital Juan Ramón Jiménez, Hospital Juan Ramon Jimenez, Juan Ramón Jiménez Hospital,
Abstract
Safety, tolerability, and quality of life (QoL) of single-agent plinabulin (Plin) for the prevention of docetaxel (Doc) chemotherapy (chemo)-induced neutropenia (CIN) in non-small cell lung cancer (NSCLC) patients (pts) from two randomized trials.Org: Stanford Cancer Institute, BeyondSpring Pharmaceuticals, Inc.,
Abstract
Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.Org: Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, University Federico II, Cimitile, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST (IRCCS) s,